Glycemia and β-cell function before and after elexacaftor/tezacaftor/ivacaftor in youth and adults with cystic fibrosis
Christine L. Chan, Andrea Granados, Amir Moheet, Sachinkumar B. Singh, Tim Vigers, Ana María Arbeláez, Yaling Yi, Shanming Hu, Andrew W. Norris, Katie Larson Ode
Abstract
Background: Diabetes is prevalent among people with CF (PwCF) and associated with worse clinical outcomes. CFTR modulators are highly effective in improving the disease course of CF. However, the effects of elexacaftor/tezacaftor/ivacaftor (ETI) on glucose metabolism in PwCF are unclear. Methods: ), were compared before and after ETI. Results: was unchanged (p = 0.67). HbA1c decreased from 5.5 % (5.5, 5.8) to 5.4 % (5.2, 5.6) (p = 0.003) while CGM variables did not change. Conclusions: ) did not change.
Topics & Concepts
IvacaftorMedicineCystic fibrosisInternal medicineInsulin resistanceInsulinDiabetes mellitusEndocrinologyImpaired glucose toleranceCarbohydrate metabolismGastroenterologyCystic fibrosis transmembrane conductance regulatorCystic Fibrosis Research AdvancesTracheal and airway disorders